Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616000644460
Ethics application status
Approved
Date submitted
13/05/2016
Date registered
18/05/2016
Date last updated
4/06/2019
Date data sharing statement initially provided
4/06/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluating decision aids for acute respiratory infections on the use of antibiotics in general practice
Scientific title
Effect of decision aids for acute respiratory infections on the use of antibiotics in general practice: a cluster randomised controlled trial
Secondary ID [1] 289211 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Acute respiratory infections 298768 0
Condition category
Condition code
Respiratory 298821 298821 0 0
Other respiratory disorders / diseases
Infection 298848 298848 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Brief name: Decision aids for ARIs
Purpose: The decision aids aim to facilitate shared decision making so that doctors and patients have a conversation about the options of using and not using antibiotics for ARIs, and that the benefits and harms of both options are considered before a decision is collaboratively reached.
Procedures: GPs will be given copies of three patient decision aids (one each for acute otitis media, sore throat, and acute bronchitis) and a brief training package (to be completed at their convenience).
Materials: Each decision aid is a two-page (double-sided) document; the training package is a short video (~15 mins) explaining about shared decision making and use of decision aids; a list of frequently asked questions (by GPs) about the decision aids will also be provided.
Who provides the intervention; The intervention package will be delivered in person by a trial researcher to GPs shortly after randomisation. No training will be provided during that visit.
When and how much: Four weeks after receiving the intervention package, a study researcher will make a brief visit (~5-10 minutes) to each practice to check if any questions. At 6 months, a study newsletter/update will be provided during another brief visit (~5-10 minutes) to answer any queries, or provide further printed copies of the decision aids if needed. After receiving the intervention, it is intended that the decision aids are used, on an ongoing basis, with applicable patients. There will be no further contact with participants following this 6 month contact, unless participants make contact with the researchers.
Tailoring: The intervention is not planned to be tailored in any way, although participants may contact and ask the research team questions about the decision aids at any time.
Fidelity: Use of the decision aids will be explored in an interview at the end of the study period.



Intervention code [1] 294749 0
Other interventions
Comparator / control treatment
'Usual care'. GPs at the control practices will not receive access to the training package or the decision aids.
The amount of contact from the research team will be the same as for the intervention group (ie brief contact about 4 weeks after randomisation and at 6 months)
Control group
Active

Outcomes
Primary outcome [1] 298289 0
Rate of antibiotic dispensing of the target antibiotics for each GP (number of consultations for which one of the target antibiotics was dispensed per year).
Target antibiotics are those routinely used for ARIs (amoxicillin, roxithromycin, amoxy-clav, cefaclor, and cephalexin)
Antibiotic dispensing data for the target antibiotics will be collected from the Pharmaceutical Benefits Scheme, by prescriber number. MBS-recorded consultations will be collected by provider number, as these are unique to the GP and the practice
Timepoint [1] 298289 0
12 month period after randomisation
For each GP, we will collect the number of antibiotics dispensed in the 12 months prior to randomisation, and in the 12 month period following randomisation
Secondary outcome [1] 323768 0
Quality of the decision-making process.
This will be measured by audiorecording a sample of consultations and analysing them using the OPTION scale and a subscale of the ACEPP tool.
Timepoint [1] 323768 0
Consultations conducting between 1 and 12 months following randomisation
Secondary outcome [2] 323769 0
GPs’ knowledge about benefits and harms of antibiotics for ARIs.
This will be assessed using a written survey adapted for this trial from previous studies.
Timepoint [2] 323769 0
Baseline and 12 months after randomisation
Secondary outcome [3] 323770 0
Adverse events (patient-initiated re-consultation for the same illness episode, chest x-ray referrals, hospital or emergency room admissions).

This data will be collected by asking GPs to keep a de-identified log of adverse events, and as needed, a review of medical records.
Timepoint [3] 323770 0
Collected throughout trial (from randomisation to 12 months after randomisation)
Secondary outcome [4] 323771 0
Acceptability, sustainability, and self-reported use of resources for antibiotic prescribing in ARIs.

Thie issues in this composite outcome will be explored in a face-to-face interview with GPs at 12 months after randomisation.
Timepoint [4] 323771 0
12 months after randomisation
Secondary outcome [5] 323809 0
Rate of antibiotic dispensing of the target antibiotics for each GP (for all antibiotics)

Antibiotic dispensing data will be collected from the Pharmaceutical Benefits Scheme.
Timepoint [5] 323809 0
12 month period after randomisation

Eligibility
Key inclusion criteria
General practice in the recruitement region
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
General practice is currently, or within the last 2 years, participated in a research study aimed at reducing antibiotic prescribing

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Practices will be randomised using a block-permuted design. The randomisation sequence will be produced by the trial statistician who will have no role in recruiting practices or consenting GPs. She will also provide allocation concealment by keeping the randomisation lists secure and only randomising practices when completed consent forms are received. The researchers responsible for recruitment will contact the statistician to randomise a practice.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Practices will be randomised using a block-permuted design. The randomisation sequence will be produced using computer-generated random numbers, by the trial statistician.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Cluster RCT
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Power calculation: From our Cochrane review of shared decision making for antibiotic prescribing, the mean absolute reduction in prescribing rate across the 10 included studies was 18%, from 47 per 100 consultations for ARIs in the control group to 29 per 100 in the intervention group; a relative rate reduction of approximately 40%. As these interventions were much more intensive and complex than our planned intervention, we have chosen to aim to detect a relative rate reduction in prescribing of 20%. For the primary outcome measure of antibiotic dispensing, power calculations suggest a required sample size of 18 practices (9 intervention, 9 control; a total of about 90 GPs, assuming an average of 5 consenting GPs per practice). With 80% power, a significance level of 5%, and an intra-class correlation coefficient for the effect of clustering of 0.15, we will require 18 practices to detect a relative 20% reduction in the rate of prescribing.

Statistical analysis:
The analysis will use Poisson regression with rate of dispensing in each month for each GP as the outcome, Using a multi-level model that accounts for nesting of monthly rates within GP, and GPs within practices. We will also collect the total number of MBS-recorded consultations for each GP for the same periods so that adjustment can be made based on the number of billed consultations for each GP. Generalised estimating equations will be used to test for the difference in mean prescribing rates (primary Poisson outcome) between intervention and control, adjusting for clustering and previous prescribing rate (mean dispensing rate in the 12 months prior to randomisation).
All practices will be included in the analysis, on an intent-to-treat basis, even if GPs did not use the decision aids, or discontinued use during the 12-month period.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
6/06/2016
Actual
20/07/2016
Date of last participant enrolment
Anticipated
Actual
29/05/2018
Date of last data collection
Anticipated
Actual
31/05/2019
Sample size
Target
90
Accrual to date
Final
122
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,TAS,VIC

Funding & Sponsors
Funding source category [1] 293592 0
Government body
Name [1] 293592 0
NHMRC
Country [1] 293592 0
Australia
Primary sponsor type
Individual
Name
Tammy Hoffmann
Address
Faculty of Health Sciences and Medicine
Bond University
University Drive
Robina, Qld 4229
Country
Australia
Secondary sponsor category [1] 292408 0
Individual
Name [1] 292408 0
Chris Del Mar
Address [1] 292408 0
Faculty of Health Sciences and Medicine
Bond University
University Drive
Robina, Qld 4229
Country [1] 292408 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 295033 0
Bond University Human Research Ethics Committee
Ethics committee address [1] 295033 0
Ethics committee country [1] 295033 0
Australia
Date submitted for ethics approval [1] 295033 0
17/03/2016
Approval date [1] 295033 0
06/05/2016
Ethics approval number [1] 295033 0
0000015433

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 65850 0
Prof Tammy Hoffmann
Address 65850 0
Faculty of Health Sciences and Medicine
Bond University
University Drive
Robina, Qld 4229
Country 65850 0
Australia
Phone 65850 0
+61 7 5595 5522
Fax 65850 0
Email 65850 0
[email protected]
Contact person for public queries
Name 65851 0
Tammy Hoffmann
Address 65851 0
Faculty of Health Sciences and Medicine
Bond University
University Drive
Robina, Qld 4229
Country 65851 0
Australia
Phone 65851 0
+61 7 5595 5522
Fax 65851 0
Email 65851 0
[email protected]
Contact person for scientific queries
Name 65852 0
Tammy Hoffmann
Address 65852 0
Faculty of Health Sciences and Medicine
Bond University
University Drive
Robina, Qld 4229
Country 65852 0
Australia
Phone 65852 0
+61 7 5595 5522
Fax 65852 0
Email 65852 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseA Brief Shared Decision-Making Intervention for Acute Respiratory Infections on Antibiotic Dispensing Rates in Primary Care: A Cluster Randomized Trial.2022https://dx.doi.org/10.1370/afm.2755
N.B. These documents automatically identified may not have been verified by the study sponsor.